Seeing Is Believing
Currently out of the existing stock ratings of Kevin Steinke, 188 are a BUY (95.43%), 9 are a HOLD (4.57%).
Analyst Kevin Steinke, currently employed carries an average stock price target met ratio of 58.45% that have a potential upside of 24.07% achieved within 217 days. Previously, Kevin Steinke worked at BARRINGTON.
Kevin Steinke’s has documented 398 price targets and ratings displayed on 19 stocks. The coverage was on Communication Services, Industrials, Energy sectors.
Most recent stock forecast was given on CCRN, Cross Country Healthcare at 10-Dec-2024.
Analyst best performing recommendations are on SMED (SHARPS COMPLIANCE CORP).
The best stock recommendation documented was for SMED (SHARPS COMPLIANCE CORP) at 6/28/2022. The price target of $6 was fulfilled within 14 days with a profit of $2.96 (97.37%) receiving and performance score of 69.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$19
8 days ago
(10-Dec-2024)
6/15 (40%)
$3.33 (21.25%)
301
Hold
$18.61
$0.55 (3.05%)
$15
13 days ago
(05-Dec-2024)
11/13 (84.62%)
$0.51 (2.82%)
57
Buy
$18
$-0.06 (-0.33%)
$19
1 months 11 days ago
(07-Nov-2024)
6/13 (46.15%)
$5.92 (49.01%)
376
Hold
$21
$2.94 (16.28%)
$32
1 years 1 months 15 days ago
(03-Nov-2023)
2/3 (66.67%)
$1.63 (8.42%)
95
Sell
$19.25
$1.19 (6.59%)
$27
1 years 1 months 16 days ago
(02-Nov-2023)
4/5 (80%)
$-0.66 (-3.31%)
56
Which stock is Kevin Steinke is most bullish on?
Which stock is Kevin Steinke is most reserved on?
What Year was the first public recommendation made by Kevin Steinke?